Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications. The company also provides XR2 Central Pharmacy System, a hospital pharmacy robotics system; Central and Satellite Pharmacy Manager, an automated pharmacy storage and retrieval system; Controlled Substance Management, a controlled substance inventory management system; OmniLinkRx, a prescription routing system; and WorkflowRx, an automated pharmacy storage, retrieval, and packaging system. In addition, it offers Omnicell Supply Management System, an automated dispensing system; Omnicell Tissue Center, which manages the chain of custody for bone and tissue specimens; OptiFlex MS that manages medical and surgical supplies; OptiFlex SS, a module for the perioperative areas; and OptiFlex CL, a module for the cardiac catheterization lab and other procedure areas. Further, the company provides IV Solutions; enterprise analytics and solutions; Omnicell Interface Software; Mach4 Pharma Systems Medimat, a robotic dispensing system; Omnicell SupplyX subscription software; RFID solutions; and consumable medication blister cards, packaging equipment, and ancillary products and services to institutional pharmacies. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Electronic computers
Sub-IndustryHealth Care Technology
SectorMedical
Current SymbolNASDAQ:OMCL
Previous Symbol
CUSIP68213N10
Phone650-251-6100
Debt
Debt-to-Equity Ratio0.27
Current Ratio1.78
Quick Ratio1.32
Price-To-Earnings
Trailing P/E Ratio398.22
Forward P/E Ratio50.48
P/E Growth4.28
Sales & Book Value
Annual Sales$716.16 million
Price / Sales3.97
Cash Flow$1.5890 per share
Price / Cash45.11
Book Value$15.63 per share
Price / Book4.59
Profitability
EPS (Most Recent Fiscal Year)$0.18
Net Income$20.60 million
Net Margins6.11%
Return on Equity7.91%
Return on Assets4.44%
Miscellaneous
Employees2,350
Outstanding Shares39,630,000
Market Cap$2.84 billion
OptionableOptionable
Omnicell (NASDAQ:OMCL) Frequently Asked Questions
What is Omnicell's stock symbol?
Omnicell trades on the NASDAQ under the ticker symbol "OMCL."
How were Omnicell's earnings last quarter?
Omnicell, Inc. (NASDAQ:OMCL) announced its quarterly earnings results on Thursday, April, 26th. The company reported $0.29 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.25 by $0.04. The business had revenue of $182.60 million for the quarter, compared to analyst estimates of $177.49 million. Omnicell had a return on equity of 7.91% and a net margin of 6.11%. The company's quarterly revenue was up 22.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.06 EPS. View Omnicell's Earnings History.
When is Omnicell's next earnings date?
What price target have analysts set for OMCL?
7 Wall Street analysts have issued 12 month target prices for Omnicell's stock. Their predictions range from $55.00 to $80.00. On average, they expect Omnicell's share price to reach $69.8571 in the next twelve months. This suggests that the stock has a possible downside of 2.5%. View Analyst Price Targets for Omnicell.
What is the consensus analysts' recommendation for Omnicell?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Omnicell.
What are Wall Street analysts saying about Omnicell stock?
Here are some recent quotes from research analysts about Omnicell stock:
- 1. According to Zacks Investment Research, "Omnicell’s third-quarter 2018 performance was impressive. The company continued to see solid uptake of Omnicell XT. It also entered various deals for the XR2 and IVX Workflow products. Bookings and product backlogs also rose in the quarter. We are encouraged to note that the company is working on product innovation through R&D. Also, Omnicell is expected to gain from launches, partnerships and digital transformation. Over the past three months, the company has outperformed its industry. However, increasing operating expenses are putting pressure on the bottom line for Omnicell. A resilient hospital capital expenditure environment might affect the adoption of the company’s solutions. Tough competitive landscape is a dampener as well." (11/14/2018)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating on OMCL shares and our 12-month price target remains at $63. After the close on Thursday, July 26, OMCL reported 2Q18 results. Revenue was slightly above our estimates and in line with FactSet consensus. Non-GAAP EPS was well above expectations. The company reiterated its view that it expects long-term organic growth of about 10-12%. The company raised its 2018 bookings guidance slightly (suggesting 14% y/y growth at the midpoint) and raised the low end of its adjusted EPS guidance range. Notable contracts in the quarter included Brigham & Women’s. We maintain our view that OMCL is poised to benefit from significant investments in its products and services." (7/26/2018)
Has Omnicell been receiving favorable news coverage?
News stories about OMCL stock have been trending very positive this week, according to InfoTrie Sentiment. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Omnicell earned a media sentiment score of 3.1 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an impact on the company's share price in the near future.
Who are some of Omnicell's key competitors?
Who are Omnicell's key executives?
Omnicell's management team includes the folowing people:
- Mr. Randall A. Lipps, Founder, Exec. Chairman, Pres & CEO (Age 61)
- Mr. Peter J. Kuipers, Exec. VP & CFO (Age 46)
- Mr. Daniel S. Johnston, Exec. VP, Chief Legal & Admin. Officer and Corp. Sec. (Age 54)
- Mr. Robin G. Seim, Pres of Global Automation & Medication Adherence (Age 58)
- Mr. Joseph Brian Spears, VP of Corp. Fin. & Chief Accounting Officer (Age 58)
Who are Omnicell's major shareholders?
Omnicell's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.90%), Conestoga Capital Advisors LLC (5.25%), Janus Henderson Group PLC (4.20%), Dimensional Fund Advisors LP (3.75%), Eagle Asset Management Inc. (2.47%) and Bank of New York Mellon Corp (2.39%). Company insiders that own Omnicell stock include Dan S Johnston, Gary S Petersmeyer, J Christopher Drew, James T Judson, Jorge R Taborga, Nhat H Ngo, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Sara J White. View Institutional Ownership Trends for Omnicell.
Which institutional investors are selling Omnicell stock?
OMCL stock was sold by a variety of institutional investors in the last quarter, including Glenmede Trust Co. NA, Eagle Asset Management Inc., Tributary Capital Management LLC, Rice Hall James & Associates LLC, Peregrine Capital Management LLC, Fort Washington Investment Advisors Inc. OH, Mutual of America Capital Management LLC and Dimensional Fund Advisors LP. Company insiders that have sold Omnicell company stock in the last year include Dan S Johnston, Gary S Petersmeyer, James T Judson, Jorge R Taborga, Nhat H Ngo, Peter J Kuipers, Randall A Lipps and Robin Gene Seim. View Insider Buying and Selling for Omnicell.
Which institutional investors are buying Omnicell stock?
OMCL stock was bought by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, BlackRock Inc., Credit Suisse AG, Conestoga Capital Advisors LLC, WINTON GROUP Ltd, Janus Henderson Group PLC, Carillon Tower Advisers Inc. and Allianz Asset Management GmbH. View Insider Buying and Selling for Omnicell.
How do I buy shares of Omnicell?
Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Omnicell's stock price today?
One share of OMCL stock can currently be purchased for approximately $71.68.
How big of a company is Omnicell?
Omnicell has a market capitalization of $2.84 billion and generates $716.16 million in revenue each year. The company earns $20.60 million in net income (profit) each year or $0.18 on an earnings per share basis. Omnicell employs 2,350 workers across the globe.
What is Omnicell's official website?
How can I contact Omnicell?
Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-251-6100 or via email at [email protected]
MarketBeat Community Rating for Omnicell (NASDAQ OMCL)
MarketBeat's community ratings are surveys of what our community members think about Omnicell and other stocks. Vote "Outperform" if you believe OMCL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMCL will underperform the S&P 500 over the long term. You may vote once every thirty days.
